Trump Administration’s Medicaid Drug Pricing Deal Set to Stir Asian Pharma Stocks
Deep News
Sep 01
Shares of Asian pharmaceutical companies could see market movement following the Trump administration’s announcement of a new drug pricing agreement with nine biotech and pharmaceutical firms. Under the terms of this deal, these companies have agreed to provide discounts on outpatient medications for state Medicaid programs. The procurement pricing for each state will be benchmarked against the overseas selling prices of these companies.
Australia’s biopharmaceutical giant CSL stated in a written declaration that it does not anticipate any significant material impact on its fiscal year 2027 results stemming from this agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.